CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,369,425 | +210.7% | 119,880 | +224.7% | 0.00% | – |
| Q1 2024 | $1,728,413 | -52.9% | 36,924 | -64.2% | 0.00% | -100.0% |
| Q4 2023 | $3,665,949 | +862.1% | 103,034 | +704.2% | 0.00% | – |
| Q3 2023 | $381,029 | -4.4% | 12,812 | -42.1% | 0.00% | – |
| Q2 2023 | $398,602 | +21.5% | 22,120 | +48.1% | 0.00% | – |
| Q1 2022 | $328,000 | +2.8% | 14,936 | -17.9% | 0.00% | – |
| Q2 2020 | $319,000 | – | 18,194 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |